Jefferies analyst Brian Tanquilut lowered his price target on Acadia Healthcare (NASDAQ: ACHC) to $85.00 (from $100.00) but maintained a Buy rating.

Tanquilut commented, "Our thesis on ACHC (strong organic growth boosted by M&A, with optionality for Medicaid-driven upside) was further validated by its strong Q4 results (8% SSS growth). While mgmt.'s FY16 guidance fell short of consensus, we would note that the shortfall was driven largely by typical conservatism, as well as FX headwinds, and the timing of ACHC's equity offering and the closing of its Priory deal; absent these factors, ACHC would have guided above expectations."

The firm lowered FY 2016 EPS from $3.05 to $2.85.

For an analyst ratings summary and ratings history on Acadia Healthcare click here. For more ratings news on Acadia Healthcare click here.

Shares of Acadia Healthcare closed at $55.00 yesterday.